docetaxel anhydrous has been researched along with taxane in 130 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (taxane) | Trials (taxane) | Recent Studies (post-2010) (taxane) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 1,288 | 210 | 779 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (5.38) | 18.2507 |
| 2000's | 36 (27.69) | 29.6817 |
| 2010's | 58 (44.62) | 24.3611 |
| 2020's | 29 (22.31) | 2.80 |
| Authors | Studies |
|---|---|
| Arbuck, SG; McGuire, WP; Trimble, EL | 1 |
| Capri, G; Fulfaro, F; Gianni, L; Tarenzi, E | 1 |
| Fojo, A | 1 |
| Auguste, L; Baselga, J; Currie, V; Edelman, B; Fennelly, D; Francis, P; Gilewski, TA; Gollub, M; Hochhauser, D; Hudis, CA; Moynahan, ME; Norton, L; O'Donaghue, M; Salvaggio, R; Seidman, AD; Spriggs, D; Tong, W; Yao, TJ | 1 |
| Bernacki, RJ; Ojima, I; Sharma, A; Straubinger, RM | 1 |
| Ohnishi, K; Ohno, R | 1 |
| Hussain, M; Jasti, BR; Parchment, RE; Vaishampayan, U | 1 |
| Bombardelli, E; Cantelmo, F; Distefano, M; Fattorossi, A; Ferlini, C; Gaggini, C; Gallo, D; Mancuso, S; Proietti, E; Riva, A; Scambia, G | 1 |
| Bollbuck, B; Downing, KH; Fojo, T; Giannakakou, P; Gussio, R; Nicolaou, KC; Nogales, E; Poy, G; Sackett, D; Zaharevitz, D | 1 |
| Bonoron-Adèle, S; Platel, D; Pouna, P; Robert, J | 1 |
| Cappuzzo, F; Green, MR; Rocha Lima, CM; Sherman, CA | 1 |
| Tashiro, H | 1 |
| Cunha, KS; de Andrade, HH; Graf, U; Reguly, ML | 1 |
| Baldini, E; Bengala, C; Conte, P; Donati, S; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Salvadori, B | 1 |
| Calafiore, AM; Gianni, L; Licata, S; Menna, P; Minotti, G; Saponiero, A; Teodori, G | 1 |
| Choy, H; Kim, JS; MacRae, R; Pyo, H | 1 |
| Mark, M; Meredith, DO; Reinhart, WH; Walter, R | 1 |
| Cassidy, PB; Fitzpatrick, FA; Kelly, RC; Moos, PJ | 1 |
| Maher, JF; Villalona-Calero, MA | 1 |
| Sparano, JA | 1 |
| Hensley, ML | 1 |
| Bleickardt, E; Kwong, MS; Murren, JR | 1 |
| Geney, R; Li, D; Ojima, I; Ungureanu, lM | 1 |
| Di Leo, A | 1 |
| Davidson, NE | 1 |
| Markman, M | 1 |
| Fountzilas, G; Gogas, H | 1 |
| Ilersich, AL; Verma, S | 1 |
| Bear, HD; Goble, S | 1 |
| Akiba, Y; Hibi, T; Hosoe, N; Ishii, H; Izumiya, M; Mori, S; Nagata, H; Suzuki, J; Takaishi, H; Ueda, T; Yamagishi, Y | 1 |
| Estévez, LG; Gradishar, WJ | 1 |
| Belinson, J; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K | 1 |
| Ensley, JF; Kim, H; Lin, HS; Lonardo, F; Oliver, J; Piechocki, MP; Shehadeh, N; Shibuya, TY; Yoo, GH; Zumstein, L | 1 |
| Joly, F; Tannock, IF | 1 |
| Itoh, N | 1 |
| Leistner, E | 1 |
| Bourstyn, E; Cuvier, C; de Roquancourt, A; Espié, M; Giacchetti, S; Hocini, H | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Fujiuchi, N; Okubo, K; Saeki, T; Takeuchi, H | 1 |
| Bhat-Nakshatri, P; Cheng, L; DeGrado, T; Gokmen-Polar, Y; Hutchins, GD; Jayaprakasan, V; Kelich, S; Miller, KD; Miller, MA; Nakshatri, H; Shanmugam, R; Sledge, GW; Sweeney, CJ; Yip-Schneider, M; Zheng, QH | 1 |
| Frense, D | 1 |
| Breen, L; Clynes, M; Keenan, J; Murphy, L | 1 |
| Ge, GB; Liu, HX; Liu, Y; Sun, J; Wang, LM; Yang, L; Zhang, JW; Zhang, YY | 1 |
| Andrade, JM; Carrara, HH; Macchetti, AH; Marana, HR; Mouro, LR; Pimentel, FF; Tiezzi, DG; Zola, FE | 1 |
| Bebek, G; Budd, GT; De, S; Downs-Kelly, E; Eng, C; Orloff, MS; Stark, GR; Tan, MH; Wesolowski, R | 1 |
| Plummer, RS; Shea, CR | 1 |
| Eastwood, A; Epstein, D; Fox, D; Rodgers, M; Soares, M; Yang, H | 1 |
| Alvarez, RD; Coleman, RL; Goodman, B; Han, HD; Katre, AA; Landen, CN; Lopez-Berestein, G; Nick, AM; Sood, AK; Steg, AD; Stone, RL | 1 |
| Kamura, T; Kuzuya, K; Noda, K; Ochiai, K; Sugiyama, T; Tamura, K; Ushijima, K | 1 |
| Harbeck, N | 1 |
| Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N | 1 |
| Bazan, F; Chaigneau, L; Compagnat, F; Dobi, E; Limat, S; Nerich, V; Perrin, S; Pivot, X; Villanueva, C; Voidey, A | 1 |
| Bhat, A; Cardonick, E; Gilmandyar, D; Somer, R | 1 |
| Bustam, AZ; Ng, CH; Phua, CE; Saad, M; Taib, NA; Teh, YC; Yip, CH; Yusof, MM | 1 |
| Durdux, C; Huguet, F; Lang, P; Monnier, L; St Guily, JL; Touboul, E | 1 |
| Dirix, LY; Dirix, M; Huget, P; Rutten, A | 1 |
| Hertz, DL; Krens, SD; McLeod, HL | 1 |
| Hatanaka, KC; Hatanaka, Y; Hosoda, M; Matsuno, Y; Taguchi, K; Takakuwa, E; Yamamoto, M; Yamashita, H; Yoshioka, T | 1 |
| Kudlowitz, D; Muggia, F | 1 |
| Deo, SV; Gogia, A; Mohanti, BK; Raina, V; Sharma, DN; Shukla, NK | 1 |
| Allen, JS; Caruthers, SD; Cui, G; Killgore, K; Kim, B; Lanza, GM; Pan, D; Schmieder, AH; Senpan, A; Shen, B; Wang, K; Wickline, SA; Yang, X; Zhang, H | 1 |
| de Bruijn, P; Ghobadi Moghaddam-Helmantel, IM; Gibson, AA; Gui, C; Hagenbuch, B; Hu, S; Mathijssen, RH; Nieuweboer, AJ; Sparreboom, A | 1 |
| Fujimoto, M; Fujisawa, Y; Kadono, T; Miyagawa, T; Nakamura, Y; Yoshino, K | 1 |
| Amiji, MM; Cacaccio, J; Coleman, TP; Ferris, CF; Ganta, S; Kulkarni, P; Patel, NR; Rawal, Y; Singh, A | 1 |
| Arnold, KM; Davis, J; Flynn, D; Opdenaker, LM; Sims-Mourtada, J | 1 |
| Burt, HM; Jackson, JK; Letchford, K; Leung, D; Wan, CPL | 1 |
| Arakawa, A; Harada-Shoji, N; Himuro, T; Hino, O; Horimoto, Y; Igari, F; Mamat, O; Saito, M; Sonoue, H; Tanabe, M; Tokuda, E; Yoshida, Y | 1 |
| Chenchik, A; Kandel, ES; Makhanov, M; Matveev, V; Zynda, ER | 1 |
| Aliño, SF; Bosó, V; de la Cueva, H; Herrero, MJ; Marqués, MR; Megias, JE; Montalar, J; Palomar, L; Poveda, JL; Rojas, L; Santaballa, A | 1 |
| Logie, J; McLaughlin, CK; Shoichet, MS; Tam, RY | 1 |
| De Iuliis, F; Giantulli, S; Giuffrida, A; Milana, B; Rubinacci, G; Salerno, G; Scarpa, S; Silvestri, I; Taglieri, L; Terella, F | 1 |
| Alvarez, RH; Barcenas, CH; Fujii, T; Kogawa, T; Le Du, F; Shen, Y; Ueno, NT; Valero, V; Xiao, L | 1 |
| Antonarakis, ES; Maughan, BL | 1 |
| Balsari, A; Bianchi, GV; Di Modica, M; Generali, D; Mariani, G; Oliviero, B; Regondi, V; Sfondrini, L; Tagliabue, E; Triulzi, T; Varchetta, S | 1 |
| Chiu, L; Chiu, N; Chow, E; Chow, R; DeAngelis, C; Lam, H; Pasetka, M; Verma, S | 1 |
| Aoki, D; Banno, K; Chiyoda, T; Hirasawa, A; Kataoka, F; Makabe, T; Ninomiya, T; Nomura, H; Sakai, K; Susumu, N; Takigawa, A; Wada, M; Yamagami, W | 1 |
| Pugliano, L; Ryan, C; Tsoi, D; White, M; Woodward, N | 1 |
| Baron, P; Beatty, J; Beitsch, P; de Snoo, FA; Dul, CL; Lee, LA; Mislowsky, A; Murray, M; Nash, C; Pellicane, JV; Rotkis, M; Stork-Sloots, L; Whitworth, P | 1 |
| Amini, M; Belderbos, JSA; Biesma, B; Bootsma, GP; Brouns, -JWM; Bussink, J; De Ruysscher, DKM; Dingemans, AC; Hendriks, LEL; Oei, SB; Stigt, JA; Uyterlinde, W; Van den Heuvel, MM; Wijsman, R | 1 |
| Augustin, D; Eichler, M; Ettl, J; Fink, V; Harbeck, N; Janni, W; Kiechle, M; Leinert, E; Rack, B; Schwentner, L; Singer, S; Weissenbacher, T; Wischnik, A | 1 |
| Bowerman, CJ; Byrne, JD; Chu, KS; Darr, DB; Deal, AM; DeSimone, JM; Keeler, AW; Luft, JC; Napier, ME; Perou, CM; Perry, JL; Schorzman, AN; Sharpless, NE; Sherwood, CA; Zamboni, WC | 1 |
| de Boer, M; Dercksen, MW; Joore, MA; Lobbezoo, DJA; Peters, FPJ; Peters, NAJB; Ramaekers, BLT; Smilde, TJ; Tjan-Heijnen, VCG; van de Wouw, AJ; van den Berkmortel, F; van Kampen, RJW; van Riel, JMG | 1 |
| Wang, H; Wang, R; Wang, Z | 1 |
| Asmar, L; Blum, JL; Brufsky, AM; Colangelo, LH; Dang, CT; Fehrenbacher, L; Flynn, PJ; Geyer, CE; Gómez, HL; Hopkins, JO; Jacobs, SA; Jeong, JH; Jones, SE; Lyss, AP; Mamounas, EP; O'Shaughnessy, JA; Paul, D; Robert, NJ; Swain, SM; Vukelja, SJ; Wolmark, N; Yothers, G | 1 |
| Bharadwaj, G; Lam, KS; Li, X; Li, Y; Macarenco, AC; Narayanan, A; Nhan, V; Shi, Y; Vieira, LS; Xiao, W; Yang, D; Yang, S | 1 |
| Armstrong, CM; Cucchiara, V; Evans, CP; Gao, AC; Gu, X; Liu, C; Lombard, AP; Lou, W | 1 |
| Boku, N; Iizumi, S; Kawai, S; Matsushima, T; Muro, K; Nagashima, K; Narita, Y; Tajika, M; Takahari, D; Takashima, A; Yasui, H | 1 |
| Brindley, DN; Chen, X; Joy, AA; Parissenti, AM; Tuszynski, J; Wang, RC; Wang, Z | 1 |
| Picard, M | 1 |
| Chavez-MacGregor, M; Giordano, SH; Niu, J; Rosenstock, AS; Wolff, AC; Zhao, H | 1 |
| Arpino, G; Bilancia, D; Bonotto, M; Bruzzese, D; Buono, G; Caputo, R; Cianniello, D; Ciccarese, M; De Laurentiis, M; De Placido, S; Fabi, A; Giuliano, M; Locci, M; Lorusso, V; Michelotti, A; Puglisi, F; Riccardi, F; Schettini, F; Veneziani, BM; Von Arx, C | 1 |
| Hu, Q; Xie, B; Xu, Z; Zhang, W; Zhang, X; Zheng, J; Zhou, J | 1 |
| Cao, T; Fan, X; Gao, Y; Li, X; Liu, Y; Peng, Y; Yang, Y; Yin, L; Yu, X; Yuan, B; Zhu, Q | 1 |
| Arving, C; Fjällskog, ML; Hellerstedt-Börjesson, S; Nordin, K; Peterson, M; Rissanen, R | 1 |
| Lin, F; Mahato, RI; Wang, X; Wen, D | 1 |
| Haukland, E; Mannsåker, B; Nieder, C; Norum, J; Pawinski, A; Yobuta, R | 1 |
| Anguera, G; Carles, J; Del Alba, AG; Domènech, M; Etxaniz, O; Fernández, PL; Font, A; Jiménez, N; López, S; Marín-Aguilera, M; Maroto, P; Mellado, B; Milà-Guasch, M; Prat, A; Reig, Ò; Ribal, MJ; Rodríguez-Vida, A; Sala-González, N; Suárez, C; Victoria, I | 1 |
| Chon, HJ; Chung, HC; Jung, M; Kang, B; Kim, C; Kim, HS; Kim, JH; Nam, CM; Rha, SY | 1 |
| Askoxylakis, V; Blaydes, R; Drummond, DC; Dumont, N; Geddie, ML; Grabow, S; Hayes, ME; Huang, ZR; Kamoun, WS; Kim, J; Kirpotin, DB; Kohli, N; Kornaga, T; Koshkaryev, A; Kuesters, G; Lugovskoy, AA; Luus, L; Marks, JD; Noble, CO; Olivier, K; Oyama, S; Pien, C; Reynolds, CP; Sawyer, AJ; Schihl, SA; Suchy, J; Tipparaju, SK; Wilton, JH; Zhou, Y | 1 |
| Au, JSK; Chan, A; Chan, CW; Cheng, HL; Leung, KT; Li, YC; Lopez, V; Molassiotis, A; Ng, TR; Suen, LKP; Sundar, R; Wong, KH; Yorke, J | 1 |
| Brunken, L; Hassan, N; Jackson, J; Mellor, C; Mitchell, E; Ng'andu, K; O'Brien, A; Paus, R; Purba, TS; Shahmalak, A; Smart, E | 1 |
| Abrams, J; Albain, KS; Badve, SS; Berenberg, JL; Brufsky, AM; Dees, EC; Desbiens, C; Ellis, MJ; Geyer, CE; Goetz, MP; Goggins, TF; Gomez, HL; Gray, RJ; Hayes, DF; Kaklamani, VG; Keane, MM; Lively, T; Mahalcioiu, C; Makower, DF; Mayer, IA; Olson, JA; Paik, S; Reddy, PS; Saphner, TJ; Sledge, GW; Sparano, JA; Toppmeyer, DL; Wagner, LI; Wood, WC | 1 |
| Calixto, JB; Campos, MM; da Costa, R; Fernandes, ES; Maia, JRLCB; Passos, GF; Quintão, NLM | 1 |
| Bai, Y; Balk, SP; Bhatt, RS; Bubley, GJ; Calagua, C; Corey, E; Giannakakou, P; Gianolio, DA; Gjyrezi, A; Khanna, P; Kung, J; Mace, S; Montgomery, B; Voznesensky, O; Wu, J; Xie, F | 1 |
| Aytes, A; Bakht, M; Beltran, H; Buisan, O; Bystrup, S; Castro, E; Conteduca, V; Font, A; Indacochea, A; Jimenez, N; Marin-Aguilera, M; Martinez-Balibrea, E; Mellado, B; Olmos, D; Palomero, L; Pardo, JC; Piulats, JM; Ruiz de Porras, V; Solé-Blanch, C; Suarez, JF; Wang, XC | 1 |
| Joerger, M; Kloft, C; Muth, M; Ojara, FW | 1 |
| Ataei, F; Bakhshoudeh, M; Hosseinkhani, S; Mehdizadeh, K | 1 |
| Abdeddaim, C; Clatot, F; Even, C; Guiard, E; Johnson, A; Perréard, M; Rambeau, A; Vauléon, E | 1 |
| Ahern, TP; Cronin-Fenton, D; Damkier, P; Ejlertsen, B; Feddersen, S; Hamilton-Dutoit, S; Hjorth, CF; Lash, TL; Rørth, M; Stage, TB; Sørensen, HT | 1 |
| Etminan, M; Maberley, D; Mikelberg, F; Sodhi, M; Yeung, SN | 1 |
| Lovell, JF; Sun, B; Zhang, Y | 1 |
| Daaka, Y; Ishov, AM; Morozov, VM; Purayil, H; Sarwar, S | 1 |
| Dilawari, A; Graham, D; Isaacs, C; Kurian, S; Lynce, F; Mainor, C; McNamara, D; Mohebtash, M; Ottaviano, Y; Pohlmann, PR; Rao, S; Swain, SM; Swanson, N; Tan, M; Warren, R; Wu, T | 1 |
| Accetta, C; Carbognin, L; D'Angelo, T; Di Giorgio, D; Di Leone, A; Fabi, A; Franceschini, G; Fuso, P; Garganese, G; Giannarelli, D; Magno, S; Masetti, R; Muratore, M; Paris, I; Pavese, F; Sanchez, AM; Scambia, G; Terribile, DA; Tiberi, G | 1 |
| Cao, M; Li, H; Lv, Z; Ma, F; Mo, H; Pan, B; Song, G; Sun, X; Teng, Y; Xu, B; Yan, X; Zhai, J; Zhao, F; Zhao, J | 1 |
| Lin, GH; Liu, XX; Wang, BC | 1 |
| Arondekar, B; Barata, PC; Ivanova, J; Last, M; Leith, A; Montgomery, R; Niyazov, A; Ribbands, A | 1 |
| Cardoso, AM; Coelho, RS; Maia, CJ; Nascimento, D; Passarinha, LA; Rocha, SM; Socorro, S | 1 |
| Costa, J; Jabaley, T; Lynch, DM; Mazzola, E; Menon, S | 1 |
| Kubota, K; Kunitoh, H; Maruyama, R; Matsuda, A; Ohira, T; Okamoto, H; Seto, T; Tsuboi, M; Yamaoka, K | 1 |
| Dang, CT; Du Toit, Y; Hurvitz, SA; Knott, A; Polito, L; Restuccia, E; Sanglier, T; Shim, J; Swain, SM | 1 |
| Contorno, T; McGwin, G; Owsley, C; Vicinanzo, MG | 1 |
| Egawa, G; Endo, Y; Fujii, H; Ishikawa, M; Kabashima, K; Yonekura, S | 1 |
| Andreucci, E; Antonuzzo, L; Biagioni, A; Bianchini, F; Calorini, L; Cianchi, F; Lulli, M; Magnelli, L; Massi, D; Messerini, L; Olivo, E; Papucci, L; Pasqualini, E; Peppicelli, S; Peri, S; Ruzzolini, J; Schiavone, N; Staderini, F; Supuran, CT; Versienti, G | 1 |
| Bakhtiary, M; Bhasin, MK; Bhasin, SS; Cheemarla, NR; Ganesan, R; Krishnan, U; Sukhatme, VP; Thomas, BE | 1 |
| Cooper, TT; Postovit, LM | 1 |
| Bialkowska, A; Gordon, C; Hillowe, A; Kaczocha, M; Ojima, I; Rizzo, RC; Trotman, LC; Wang, L | 1 |
| Thomas, C | 1 |
| Ai, X; Hao, X; Lei, S; Li, W; Wang, Y; Xu, H; Yang, G; Yang, Y; Zhang, S | 1 |
38 review(s) available for docetaxel anhydrous and taxane
| Article | Year |
|---|---|
Options for primary chemotherapy of epithelial ovarian cancer: taxanes.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds; Bridged-Ring Compounds; Cisplatin; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Remission Induction; Taxoids | 1994 |
The role of taxanes in the treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Taxoids | 1996 |
Taxanes.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Paclitaxel; Taxoids | 1996 |
[New antitumor drugs for non-Hodgkin's lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Paclitaxel; Prednisone; Rituximab; Taxoids; Vincristine | 1998 |
Taxanes: an overview of the pharmacokinetics and pharmacodynamics.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Docetaxel; Drug Interactions; Humans; Male; Mitosis; Molecular Structure; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Vinblastine; Vinorelbine | 2000 |
[Standard chemotherapy for metastatic breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Paclitaxel; Practice Guidelines as Topic; Prognosis; Taxoids | 2000 |
Epirubicin/taxane combinations in breast cancer: experience from several Italian trials.
Topics: Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Drug Therapy, Combination; Epirubicin; Female; Humans; Italy; Meta-Analysis as Topic; Paclitaxel; Taxoids | 2001 |
Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Guidelines as Topic; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Taxanes and capecitabine in combination: rationale and clinical results.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Synergism; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2002 |
Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Female; Genes, erbB-2; Humans; Infusions, Intravenous; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2002 |
Camptothecin and taxane regimens for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Small Cell; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Overcoming multidrug resistance in taxane chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Bridged-Ring Compounds; Clinical Trials as Topic; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Models, Molecular; Paclitaxel; Taxoids | 2002 |
The European experience with docetaxel in the treatment of early-stage breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Europe; Female; Genes, p53; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Ongoing US cooperative group trials using taxanes in the adjuvant setting.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Risk Factors; Taxoids; Trastuzumab; United States | 2002 |
Managing taxane toxicities.
Topics: Antineoplastic Agents, Phytogenic; Arthralgia; Bridged-Ring Compounds; Docetaxel; Drug Hypersensitivity; Humans; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Thrombocytopenia | 2003 |
The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Clinical Trials as Topic; Docetaxel; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2003 |
Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2003 |
Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
[Chemotherapy for prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bridged-Ring Compounds; Docetaxel; Drug Resistance; Drug Therapy, Combination; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Palliative Care; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2005 |
[Neoadjuvant treatment of early breast cancer: new drugs contribution].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2004 |
[Current status of adjuvant chemotherapy for breast cancer].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Menopause; Perioperative Care; Tamoxifen; Taxoids; Trastuzumab | 2006 |
Taxanes: perspectives for biotechnological production.
Topics: Bridged-Ring Compounds; Cell Culture Techniques; Docetaxel; Molecular Structure; Paclitaxel; Taxoids; Taxus | 2007 |
Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2011 |
Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature.
Topics: Antineoplastic Agents; Birth Weight; Breast Neoplasms; Bridged-Ring Compounds; Cohort Studies; Docetaxel; Female; Gestational Age; Humans; Ovarian Neoplasms; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Retrospective Studies; Taxoids | 2012 |
Trastuzumab emtansine in breast cancer.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
Defining risks of taxane neuropathy: insights from randomized clinical trials.
Topics: Axons; Bridged-Ring Compounds; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Nanoparticles; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Taxoids | 2013 |
Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Humans; Platinum Compounds; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2015 |
Taxane-induced arthralgia and myalgia: A literature review.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arthralgia; Bridged-Ring Compounds; Docetaxel; Humans; Myalgia; Taxoids | 2017 |
Management of patients treated with pertuzumab in the Australian clinical practice setting.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Bridged-Ring Compounds; Disease Management; Disease Progression; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2016 |
Management of Hypersensitivity Reactions to Taxanes.
Topics: Allergens; Animals; Antineoplastic Agents; Bridged-Ring Compounds; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Humans; Paclitaxel; Skin Tests; Taxoids | 2017 |
Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Docetaxel; Humans; Paclitaxel; Taxoids | 2020 |
Role of TDM-based dose adjustments for taxane anticancer drugs.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2021 |
Current development of cabazitaxel drug delivery systems.
Topics: Antineoplastic Agents; Docetaxel; Drug Delivery Systems; Humans; Male; Taxoids | 2023 |
A Bayesian network analysis of immunotherapy and taxane chemotherapy as second- or later-line treatments in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immunotherapy; Lung Neoplasms | 2022 |
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Receptors, Estrogen | 2023 |
[Role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) treatment: still standard or exception?]
Topics: Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2023 |
12 trial(s) available for docetaxel anhydrous and taxane
| Article | Year |
|---|---|
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Taxoids | 1996 |
Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Budgets; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Neoplasm Metastasis; Ontario; Paclitaxel; Population Surveillance; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine; Women's Health | 2003 |
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Topics: Adult; Aged; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Taxoids | 2013 |
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fever; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Remission Induction; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Decision-Making; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gene Expression Profiling; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Mastectomy, Segmental; Middle Aged; Molecular Typing; Neoadjuvant Therapy; Nitriles; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Registries; Tamoxifen; Taxoids; Treatment Outcome; Triazoles; Young Adult | 2017 |
Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Cost-Benefit Analysis; Disease Progression; Docetaxel; Female; Health Resources; Humans; Kaplan-Meier Estimate; Netherlands; Paclitaxel; Quality-Adjusted Life Years; Receptor, ErbB-2; Taxoids | 2017 |
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2017 |
Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bridged-Ring Compounds; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Prospective Studies; Stomach Neoplasms; Taxoids | 2019 |
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome; Young Adult | 2020 |
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Docetaxel; Female; Humans; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab | 2022 |
Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Taxoids | 2023 |
80 other study(ies) available for docetaxel anhydrous and taxane
| Article | Year |
|---|---|
Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Docetaxel; Drug Carriers; Female; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bridged-Ring Compounds; Cell Cycle; DNA, Neoplasm; Docetaxel; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Humans; Mice; Mice, Nude; Paclitaxel; Taxoids; Transplantation, Heterologous; Tubulin; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2000 |
A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.
Topics: Alkaloids; Antineoplastic Agents; Bridged-Ring Compounds; Diterpenes; Docetaxel; Drug Resistance, Neoplasm; Epothilones; Epoxy Compounds; Humans; Inhibitory Concentration 50; Models, Chemical; Models, Molecular; Mutation; Paclitaxel; Protein Conformation; Structure-Activity Relationship; Taxoids; Thiazoles; Tubulin; Tumor Cells, Cultured | 2000 |
Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.
Topics: Animals; Anthracyclines; Bridged-Ring Compounds; Chemotherapy, Cancer, Regional Perfusion; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Combinations; Drug Synergism; Epirubicin; Heart; Liver; Male; Paclitaxel; Rats; Rats, Sprague-Dawley; Taxoids | 2000 |
Taxanes: the genetic toxicity of paclitaxel and docetaxel in somatic cells of Drosophila melanogaster.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Bridged-Ring Compounds; Docetaxel; Drosophila melanogaster; Female; Genetic Markers; Larva; Male; Mutagenicity Tests; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2001 |
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Heart; Humans; Myocardium; Paclitaxel; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2001 |
Commercial taxane formulations induce stomatocytosis and increase blood viscosity.
Topics: Aged; Antineoplastic Agents, Phytogenic; Blood Viscosity; Bridged-Ring Compounds; Cardiovascular System; Docetaxel; Dose-Response Relationship, Drug; Erythrocytes; Female; Humans; Male; Middle Aged; Paclitaxel; Rheology; Surface-Active Agents; Taxoids; Time Factors | 2001 |
Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: structure-activity relationships and their implications.
Topics: Animals; Antineoplastic Agents, Phytogenic; Binding, Competitive; Bridged-Ring Compounds; Cells, Cultured; Cyclooxygenase 2; Docetaxel; Enzyme Induction; Humans; Immunoenzyme Techniques; Isoenzymes; Macrophages; Membrane Proteins; Mice; Microtubules; Molecular Structure; Monocytes; Paclitaxel; Prostaglandin-Endoperoxide Synthases; Receptors, Cell Surface; Structure-Activity Relationship; Taxoids; Tubulin | 2002 |
[A case of recurrent pleural effusion and positive cytology of advanced gastric cancer treated by TS-1 plus weekly taxane as second-line chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-19-9 Antigen; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Oxonic Acid; Pleural Effusion, Malignant; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Topotecan | 2004 |
Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Enterovirus; Genetic Therapy; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Protein Biosynthesis; Taxoids; Transduction, Genetic; Tumor Suppressor Protein p53 | 2004 |
Chemotherapy for patients with hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Clinical Trials, Phase III as Topic; Diphosphonates; Docetaxel; Glucocorticoids; Humans; Hydrocortisone; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2004 |
[Drugs from nature. The biology of taxane].
Topics: Animals; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Docetaxel; Humans; Taxoids; Taxus | 2005 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.
Topics: Androgen Antagonists; Anilides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Synergism; Endothelium, Vascular; Fibroblast Growth Factor 2; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Nitriles; Prostatic Neoplasms; Radionuclide Imaging; Sesquiterpenes; Taxoids; TNF Receptor-Associated Factor 1; TNF Receptor-Associated Factor 2; Tosyl Compounds; Umbilical Veins; Vascular Endothelial Growth Factor A | 2006 |
Development of taxane resistance in a panel of human lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bridged-Ring Compounds; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Survival; Docetaxel; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Taxoids | 2008 |
C-7 configuration as one of determinants in taxanes metabolism by human cytochrome P450 enzymes.
Topics: Bridged-Ring Compounds; Chromatography, Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Docetaxel; Enzyme Inhibitors; Female; Humans; Hydroxylation; Isoenzymes; Kinetics; Male; Microsomes, Liver; Molecular Conformation; Paclitaxel; Recombinant Proteins; Taxoids | 2009 |
Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Taxoids | 2011 |
Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Cell Line, Tumor; Cluster Analysis; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; HEK293 Cells; Humans; Kinesins; Middle Aged; Neoplasm Staging; Paclitaxel; Protein Binding; Taxoids; Vincristine | 2012 |
Dermatopathologic effects of taxane therapy.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Biopsy; Breast Neoplasms; Bridged-Ring Compounds; Cell Cycle; Docetaxel; Female; Humans; Leiomyosarcoma; Male; Mitosis; Paclitaxel; Skin; Skin Diseases; Taxoids | 2011 |
Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bridged-Ring Compounds; Calcium-Binding Proteins; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Endothelial Cells; Epithelial Cells; Female; Hedgehog Proteins; Humans; Intercellular Signaling Peptides and Proteins; Jagged-1 Protein; Kruppel-Like Transcription Factors; Membrane Proteins; Mice; Molecular Targeted Therapy; Neovascularization, Pathologic; Nuclear Proteins; Ovarian Neoplasms; Receptors, Notch; RNA Interference; RNA, Small Interfering; Serrate-Jagged Proteins; Stromal Cells; Taxoids; Transcription Factors; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2011 |
Breast cancer: Increasing therapy options for HER2-positive early breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cyclophosphamide; Disease Progression; Docetaxel; Female; Genes, erbB-2; Humans; Taxoids; Time Factors; Trastuzumab | 2011 |
First-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2012 |
Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cause of Death; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fever; Fluorouracil; Humans; Malaysia; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Taxoids | 2012 |
Hypofractionated palliative radiotherapy for advanced head and neck cancer: the IHF2SQ regimen.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Palliative Care; Radiotherapy; Retrospective Studies; Sex Factors; Taxoids | 2013 |
Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Drug Monitoring; Female; Humans; Neoplasms; Paclitaxel; Pharmacogenetics; Precision Medicine; Taxoids | 2013 |
Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2014 |
Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Bridged-Ring Compounds; Cells, Cultured; Docetaxel; Endothelial Cells; Fluorocarbons; Integrin alphaVbeta3; Nanoparticles; Neoplasms, Experimental; Neovascularization, Pathologic; Phospholipases; Prodrugs; Rabbits; Taxoids | 2014 |
Influence of drug formulation on OATP1B-mediated transport of paclitaxel.
Topics: Animals; Antineoplastic Agents; Biological Transport; Bridged-Ring Compounds; Cell Line; Chemistry, Pharmaceutical; CHO Cells; Cricetulus; Docetaxel; Drug Interactions; HEK293 Cells; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Mice; Mice, Inbred DBA; Mice, Knockout; Oocytes; Organic Anion Transporters; Paclitaxel; Taxoids; Tissue Distribution; Xenopus laevis | 2014 |
Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Scalp; Skin Neoplasms; Taxoids; Treatment Outcome | 2014 |
Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Bridged-Ring Compounds; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Docetaxel; Drug Carriers; Drug Delivery Systems; Drug Resistance, Multiple; Emulsions; Female; Folic Acid; Gadolinium; Humans; Mice; Mice, Nude; Nanoparticles; Ovarian Neoplasms; Particle Size; Taxoids; Theranostic Nanomedicine | 2016 |
Taxane-induced hedgehog signaling is linked to expansion of breast cancer stem-like populations after chemotherapy.
Topics: Apoptosis; Breast Neoplasms; Bridged-Ring Compounds; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; MCF-7 Cells; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Signal Transduction; Taxoids | 2015 |
Mixed molecular weight copolymer nanoparticles for the treatment of drug-resistant tumors: formulation development and cytotoxicity.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Bridged-Ring Compounds; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Delayed-Action Preparations; Docetaxel; Drug Carriers; Drug Resistance, Neoplasm; Humans; Micelles; Molecular Weight; Nanoparticles; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols; Polymers; Taxoids | 2014 |
Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma, Ductal, Breast; Cell Line, Tumor; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression; Gene Knockdown Techniques; Hepatocyte Nuclear Factor 3-alpha; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2015 |
Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.
Topics: Bridged-Ring Compounds; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Docetaxel; Humans; Male; Paclitaxel; Prostatic Neoplasms; Protein Kinase Inhibitors; Taxoids | 2014 |
SNPs and taxane toxicity in breast cancer patients.
Topics: Aged; Breast Neoplasms; Bridged-Ring Compounds; Cytochrome P-450 CYP3A; DNA-Binding Proteins; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Endonucleases; Female; Genetic Association Studies; Humans; Middle Aged; Mucositis; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids | 2014 |
Innovative use of the taxol binding peptide overcomes key challenges of stable and high drug loading in polymeric nanomicelles.
Topics: Amino Acid Sequence; Antineoplastic Agents; Binding Sites; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Delivery Systems; Humans; Micelles; Molecular Sequence Data; Neoplasms; Paclitaxel; Peptides; Polyethylene Glycols; Taxoids | 2015 |
Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Phenotype; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survivin; Taxoids; Up-Regulation | 2016 |
Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.
Topics: Androstenes; Androstenols; Benzamides; Bridged-Ring Compounds; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Taxoids | 2015 |
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
Topics: Animals; Antibodies, Blocking; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Bridged-Ring Compounds; Cell Line, Tumor; Cells, Cultured; Docetaxel; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Histocompatibility Antigens Class I; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Mice, SCID; NK Cell Lectin-Like Receptor Subfamily K; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Trastuzumab; Xenograft Model Antitumor Assays | 2016 |
Retrospective Analysis on the Feasibility and Efficacy of Docetaxel-Cisplatin Therapy for Recurrent Endometrial Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Survival; Docetaxel; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Risk Factors; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
Topics: Adolescent; Adult; Age Factors; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Longitudinal Studies; Middle Aged; Multicenter Studies as Topic; Patient Compliance; Practice Guidelines as Topic; Prospective Studies; Quality of Life; Surveys and Questionnaires; Taxoids; Young Adult | 2017 |
Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Bridged-Ring Compounds; Cell Survival; Docetaxel; Drug Carriers; Drug Liberation; Drug Resistance, Neoplasm; Female; Humans; Lactic Acid; Mice, Nude; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Surface Properties; Taxoids; Triple Negative Breast Neoplasms | 2017 |
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Bridged-Ring Compounds; Diagnostic Imaging; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Microtubules; Taxoids; Tubulin; Tumor Cells, Cultured | 2017 |
Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Cell Line, Tumor; Cholic Acid; Docetaxel; Drug Carriers; Humans; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Taxoids | 2017 |
ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
Topics: Androgen Antagonists; ATP Binding Cassette Transporter, Subfamily B; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms; Receptors, Androgen; Taxoids | 2017 |
Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Docetaxel; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Taxoids; Tegafur | 2017 |
Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Bridged-Ring Compounds; Chromatin; Colchicine; Docetaxel; Drug Resistance, Neoplasm; Humans; MCF-7 Cells; Microtubules; Taxoids; Vinca Alkaloids | 2017 |
Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
Topics: Acute Disease; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Leukemia, Myeloid; Medicare; Myelodysplastic Syndromes; Neoplasm Staging; Registries; Risk Factors; SEER Program; Taxoids; Texas; United States | 2018 |
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Disease-Free Survival; Docetaxel; Female; Humans; Italy; Middle Aged; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2018 |
Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
Topics: Biomarkers, Tumor; Bridged-Ring Compounds; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Mutation; Neoplastic Stem Cells; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2018 |
FOXM1 contributes to taxane resistance by regulating UHRF1-controlled cancer cell stemness.
Topics: Animals; Bridged-Ring Compounds; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Phenotype; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Binding; Signal Transduction; Taxoids; Ubiquitin-Protein Ligases | 2018 |
Colored body images reveal the perceived intensity and distribution of pain in women with breast cancer treated with adjuvant taxanes: a prospective multi-method study of pain experiences.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Pain; Pain Measurement; Prospective Studies; Taxoids | 2018 |
Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Chalcones; Delayed-Action Preparations; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Micelles; MicroRNAs; Neoplastic Stem Cells; PC-3 Cells; Prostatic Neoplasms; Taxoids | 2019 |
Initiation of Systemic Therapy During the Last 30 Days of Life in Patients With Metastatic Castration-resistant Prostate Cancer.
Topics: Aged; Bridged-Ring Compounds; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Terminal Care; Treatment Outcome | 2019 |
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
Topics: Benzamides; Biomarkers, Tumor; Bridged-Ring Compounds; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Knockout Techniques; Humans; Male; Nitriles; Oncogene Proteins, Fusion; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Transcriptional Regulator ERG | 2019 |
Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models.
Topics: Animals; Antineoplastic Agents; Bridged-Ring Compounds; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Docetaxel; Humans; Liposomes; Mice, Inbred NOD; Mice, SCID; Nanoparticles; Receptor, EphA2; Taxoids; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Cancer Care Facilities; Cisplatin; Docetaxel; Female; Hong Kong; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Platinum Compounds; Prevalence; Prospective Studies; Quality of Life; Risk Factors; Taxoids | 2019 |
CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane-induced alopecia.
Topics: Alopecia; Antineoplastic Agents; Bridged-Ring Compounds; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Docetaxel; Humans; Keratinocytes; Models, Theoretical; Organ Culture Techniques; Paclitaxel; Piperazines; Protein Kinase Inhibitors; Pyridines; Stem Cells; Taxoids | 2019 |
Taxane resistance in prostate cancer is mediated by decreased drug-target engagement.
Topics: Animals; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Nude; Microtubules; Prostatic Neoplasms; Taxoids | 2020 |
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Docetaxel; Humans; Male; Mice; Platinum; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-bcl-2; Taxoids | 2021 |
Upregulation of apoptotic protease activating factor-1 expression correlates with anti-tumor effect of taxane drug.
Topics: Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Bridged-Ring Compounds; Docetaxel; Dose-Response Relationship, Drug; Humans; MCF-7 Cells; Taxoids; Up-Regulation | 2021 |
Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Aged; Bridged-Ring Compounds; Disease Progression; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2021 |
Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark.
Topics: Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cohort Studies; Cytochrome P-450 CYP3A; Denmark; Docetaxel; Female; Humans; Liver-Specific Organic Anion Transporter 1; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; Taxoids | 2022 |
Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Child; Docetaxel; Female; Humans; Lacrimal Apparatus Diseases; Macular Edema; Middle Aged; Optic Nerve Diseases; Paclitaxel; Retrospective Studies; Tamoxifen; Taxoids | 2022 |
Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer.
Topics: Androgens; Bridged-Ring Compounds; Cell Cycle Proteins; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Androgen; Taxoids | 2022 |
Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer.
Topics: Adult; Alopecia; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Paclitaxel; Prospective Studies; Scalp; Taxoids | 2022 |
Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Prospective Studies; Quality of Life; Taxoids | 2022 |
Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2023 |
STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Humans; Male; Oxidoreductases; Paclitaxel; Prostate; Prostatic Neoplasms; Taxoids | 2023 |
A Three-Step Taxane Titration Protocol Decreases Hypersensitivity Reactions During First and Second Exposures.
Topics: Docetaxel; Drug Hypersensitivity; Epinephrine; Humans; Paclitaxel; Prospective Studies; Taxoids | 2023 |
Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records.
Topics: Breast Neoplasms; Docetaxel; Electronic Health Records; Female; Humans; Paclitaxel; Retrospective Studies; Taxoids; Trastuzumab | 2023 |
The Association Between Taxane Use and Lacrimal Disorders.
Topics: Docetaxel; Humans; Lacrimal Apparatus Diseases; Paclitaxel; Taxoids; United States | 2023 |
Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hemangiosarcoma; Humans; Paclitaxel; Skin Neoplasms; Taxoids | 2023 |
The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane-derived, and platinum-based drugs.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Cell Line; Cell Line, Tumor; Docetaxel; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Stomach Neoplasms; Taxoids | 2023 |
Taxane chemotherapy induces stromal injury that leads to breast cancer dormancy escape.
Topics: Animals; Cytokines; Docetaxel; Granulocyte Colony-Stimulating Factor; Interleukin-6; Mice; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Taxoids | 2023 |
Wounding the stroma: Docetaxel's role in dormant breast cancer escape.
Topics: Bridged-Ring Compounds; Cytokines; Docetaxel; Neoplasms; Taxoids | 2023 |
Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells.
Topics: ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Fatty Acid-Binding Proteins; Humans; Male; Prostatic Neoplasms; Taxoids | 2023 |
Immunotherapy as a later-line option for
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms; Paclitaxel; Taxoids | 2023 |